Critical Review: Tilray Brands (NASDAQ:TLRY) vs. InterCure (NASDAQ:INCR)

Tilray Brands (NASDAQ:TLRY) and InterCure (NASDAQ:INCR) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, dividends, analyst recommendations and valuation.

Risk & Volatility

Tilray Brands has a beta of 1.91, suggesting that its stock price is 91% more volatile than the S&P 500. Comparatively, InterCure has a beta of 1.43, suggesting that its stock price is 43% more volatile than the S&P 500.

Institutional & Insider Ownership

9.3% of Tilray Brands shares are held by institutional investors. Comparatively, 8.3% of InterCure shares are held by institutional investors. 0.8% of Tilray Brands shares are held by insiders. Comparatively, 0.2% of InterCure shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Tilray Brands and InterCure’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tilray Brands	-13.11%	-7.76%	-5.59%
InterCure	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of current ratings for Tilray Brands and InterCure, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tilray Brands	2	2	2	1	2.29
InterCure	1	0	0	0	1.00

Tilray Brands currently has a consensus price target of $7.00, suggesting a potential upside of 93.91%. Given Tilray Brands’ stronger consensus rating and higher possible upside, research analysts clearly believe Tilray Brands is more favorable than InterCure.

Earnings & Valuation

This table compares Tilray Brands and InterCure”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tilray Brands	$915.45 million	0.54	-$121.40 million	($1.08)	-3.34
InterCure	$78.47 million	0.76	-$10.37 million	$0.15	36.13

InterCure has lower revenue, but higher earnings than Tilray Brands. Tilray Brands is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Summary

Tilray Brands beats InterCure on 8 of the 15 factors compared between the two stocks.

About Tilray Brands

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada.

About InterCure

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.